Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

JAK inhibitors do not increase cancer risk in severe alopecia areata compared to traditional treatments.

Systemic therapy may reduce male infertility in psoriasis patients.

Alopecia totalis/universalis is linked to more autoimmune diseases than patchy alopecia areata.

5-alpha reductase inhibitors do not increase osteoporosis risk in women with certain hair loss conditions.

Nocturia cases increased, but medication use declined, suggesting under-treatment.

Using 5α-reductase inhibitors for hair loss may increase the risk of dry eye disease.

Drug repurposing can create safer, cheaper treatments by finding new uses for existing drugs.

Using 5-alpha reductase inhibitors may lower the risk of breast cancer in females.

People with hidradenitis suppurativa have a higher risk of kidney stones.

GLP-1RA therapy may increase the risk of hair loss.

Long-COVID causes more health issues after COVID-19, varying by age, sex, and infection wave.

Alopecia areata patients often face mental health issues like anxiety and depression.

5-alpha reductase inhibitors and spironolactone don't increase gynecological tumor risk, glucagon-like-peptide-1 receptor agonists may increase alopecia risk, sanitary pads can cause dermatitis, early hidradenitis suppurativa intervention is crucial for Hispanic patients, community education boosts skin cancer awareness, metformin may improve skin cancer survival, LNG-IUDs can increase acne risk, machine learning accurately detects basal cell carcinoma, JAK-inhibitors may raise miscarriage risk, inclusive skincare ads affect those with darker skin, and CCCA in Black women might involve autoimmunity.

Dupilumab users have a higher risk of developing alopecia areata.

IBS is linked to certain skin conditions like psoriasis and rosacea, and vice versa.

Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.

Long COVID affects over half of COVID-19 survivors, causing a range of symptoms like fatigue and neurological issues, with no specific treatment yet.

GLP-1 receptor agonists may help or harm hair health, needing more research.

Oral 5-alpha-reductase inhibitors for hair loss don't increase heart risk.

Finasteride may lower depression risk in younger men with hair loss but increase it in older men with prostate issues.

Taking medication for hair loss might cause sexual problems.

GLP-1RAs, like semaglutide and tirzepatide, may cause hair loss, so patients should be informed and monitored.

GLP-1 agonists may help treat certain skin conditions.

Long-term exposure to air pollution increases the risk of hair loss.

GLP-1 receptor agonists may help manage and prevent diabetic foot ulcers.

The effect of GLP-1 RAs on erectile function is unclear and needs more research.

CRT is more effective than oral minoxidil alone for treating hair loss.

GLP-1RAs may cause hair loss but could also help regrow hair in some cases.

Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.